Validation of NEDD8-Conjugating Enzyme UBC12 As a New Therapeutic Target in Lung Cancer

2019 ◽  
Author(s):  
Lihui Li ◽  
Jihui Kang ◽  
Wenjuan Zhang ◽  
Lili Cai ◽  
Shiwen Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Target ◽  
Conjugating Enzyme

scholarly journals Validation of NEDD8-conjugating enzyme UBC12 as a new therapeutic target in lung cancer

EBioMedicine ◽  
2019 ◽  
Vol 45 ◽  
pp. 81-91 ◽  
Author(s):  
Lihui Li ◽  
Jihui Kang ◽  
Wenjuan Zhang ◽  
Lili Cai ◽  
Shiwen Wang ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Target ◽  
Conjugating Enzyme

CD26 is overexpressed in lung adenocarcinoma and qualifies as a therapeutic target against lung cancer

2018 ◽  
Author(s):  
N Enz ◽  
F Janker ◽  
F Ramírez Fragoso ◽  
M Haberecker ◽  
A Soltermann ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Lung Adenocarcinoma ◽  
Therapeutic Target

scholarly journals Predicting ROR1/BCL2 combination targeted therapy of small cell carcinoma of the lung

2021 ◽  
Vol 12 (6) ◽  
Author(s):  
Walter Z. Wang ◽  
Konstantin Shilo ◽  
Joseph M. Amann ◽  
Alyssa Shulman ◽  
Mohammad Hojjat-Farsangi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Targeted Therapy ◽  
Small Cell Lung Cancer ◽  
Cell Lines ◽  
Cell Lung Cancer ◽  
Therapeutic Target ◽  
Small Cell ◽  
Orphan Receptor ◽  
Small Cell Lung ◽  
Sclc Patient

AbstractSmall cell lung cancer (SCLC) remains a deadly form of cancer, with a 5-year survival rate of less than 10 percent, necessitating novel therapies. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) is an oncofetal protein that is emerging as a therapeutic target and is co-expressed with BCL2 in multiple tumor types due to microRNA coregulation. We hypothesize that ROR1-targeted therapy is effective in small cell lung cancer and synergizes with therapeutic BCL2 inhibition. Tissue microarrays (TMAs) and formalin-fixed paraffin-embedded (FFPE) SCLC patient samples were utilized to determine the prevalence of ROR1 and BCL2 expression in SCLC. Eight SCLC-derived cell lines were used to determine the antitumor activity of a small molecule ROR1 inhibitor (KAN0441571C) alone and in combination with the BCL2 inhibitor venetoclax. The Chou-Talalay method was utilized to determine synergy with the drug combination. ROR1 and BCL2 protein expression was identified in 93% (52/56) and 86% (48/56) of SCLC patient samples, respectively. Similarly, ROR1 and BCL2 were shown by qRT-PCR to have elevated expression in 79% (22/28) and 100% (28/28) of SCLC patient samples, respectively. KAN0441571C displayed efficacy in 8 SCLC cell lines, with an IC50 of 500 nM or less. Synergy as defined by a combination index of <1 via the Chou-Talalay method between KAN0441571C and venetoclax was demonstrated in 8 SCLC cell lines. We have shown that ROR1 inhibition is synergistic with BCL2 inhibition in SCLC models and shows promise as a novel therapeutic target in SCLC.

scholarly journals Survivin As a Therapeutic Target for Radiation Sensitization in Lung Cancer

2004 ◽  
Vol 64 (8) ◽  
pp. 2840-2845 ◽  
Author(s):  
Bo Lu ◽  
Yi Mu ◽  
Carolyn Cao ◽  
Fenghua Zeng ◽  
Sylke Schneider ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Target ◽  
Radiation Sensitization

scholarly journals Validation of L-Myc as a viable therapeutic target in small cell lung cancer

2016 ◽  
Vol 11 (2) ◽  
pp. S28-S29
Author(s):  
Dong-Wook Kim ◽  
Colin Thomas Dunn ◽  
Julien Sage ◽  
Kwon-Sik Park
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Therapeutic Target ◽  
Small Cell ◽  
Small Cell Lung

scholarly journals Identification of Myc-associated protein with JmjC domain as a novel therapeutic target oncogene for lung cancer

2007 ◽  
Vol 6 (2) ◽  
pp. 542-551 ◽  
Author(s):  
Chie Suzuki ◽  
Koji Takahashi ◽  
Satoshi Hayama ◽  
Nobuhisa Ishikawa ◽  
Tatsuya Kato ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Therapeutic Target ◽  
Jmjc Domain ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document